Awards recognize goBalto's Select in the 'Best Sponsor-Focused Technological Development' category
SAN FRANCISCO, March 14, 2017 -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, has been named a finalist in the 'Best Sponsor-Focused Technological Development' category for the 2017 Clinical Research & Excellence (CARE) Awards. goBalto Select, a SaaS solution for optimizing site selection – a perpetual bottleneck in starting clinical trials – has been shortlisted for the inaugural awards, which take place in Boston on April 5, 2017.
The CARE Awards provide the industry with an opportunity to acknowledge and applaud its highest achievers across all parts of the value chain, and to recognize both corporate and individual achievement.
Study Startup (SSU) refers to a series of steps performed before a clinical trial begins. These steps typically include activities such as country selection, pre-study visits, site selection and initiation, regulatory document submission, contract and budget negotiations, and enrolling the first patient. Since each of these steps has multiple components, delays in study timelines are commonplace.
"The CARE Awards' recognition of goBalto's solution for site identification, feasibility, and selection supports our continued efforts, and that of our customers and partners, to accelerate the clinical trials process; we are honored that our technology has been acknowledged among the best solutions in the industry," said Sujay Jadhav, goBalto's CEO.
With recent multiple enterprise expansions, goBalto now services more than two-thirds of the top 25 global pharmas and three of the top five CROs, having the largest industry-proven set of country specific regulatory business process workflows and associated in-depth activation metrics.
"Today, the industry still predominantly relies on unsophisticated and inconsistent practices for SSU. Our nomination reflects goBalto's commitment to the innovation needed to mitigate risk, ensure compliance, reduce cycle times, minimize costs, and ultimately enable valuable therapies to get to patients sooner," added Jadhav.